Ripple Therapeutics is a clinical-stage company specializing in the development of advanced drug delivery systems for ophthalmic therapeutics. Utilizing its proprietary Epidel technology, Ripple Therapeutics engineers drugs into controlled release pharmaceuticals and medical device coatings without the need for polymers or excipients. This technology allows for the creation of implantable forms such as cylinders and microspheres, which deliver drugs in a highly predictable manner based on surface erosion. The company operates in the pharmaceutical and medical device markets, focusing on clients in the ophthalmology sector. Ripple Therapeutics generates revenue through licensing deals, such as their agreement with Laboratoires for North America and Europe, and aims to achieve commercial success through innovative product development and strategic partnerships. The company is led by a seasoned leadership team experienced in managing both small and large public and private companies through various stages of growth and financing strategies, including venture capital, M&A transactions, IPOs, and PIPEs. Ripple Therapeutics also invests in the future by providing meaningful work experiences for university students through co-operative education programs.

Keywords: drug delivery, ophthalmic therapeutics, controlled release, Epidel technology, medical device coatings, implantable forms, surface erosion, licensing deals, clinical-stage, pharmaceutical innovation.